Utilization of Engineered Skeletal Muscle Units to Repair Volumetric Muscle
利用工程骨骼肌单位修复体积肌
基本信息
- 批准号:9274917
- 负责人:
- 金额:$ 47.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-07-01 至 2020-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdultAnimalsAreaBehaviorBiologyBlood VesselsBlood capillariesBrainBurn injuryCaliberCategoriesCellsClinicalComplexDevelopmentDiseaseEngineeringEngraftmentEnvironmentExhibitsExtracellular MatrixFaceFacial MusclesFemaleGenerationsGoalsHandHumanImmunologic MarkersImplantInjuryKidneyLaboratoriesLeadLigamentsLiverLungMalignant NeoplasmsMammalsMethodologyModelingMonitorMorbidity - disease rateMuscleMuscle CellsMuscle FibersMuscle functionMuscular AtrophyMusculoskeletalMyopathyNatural regenerationNerveNeuromuscular JunctionOperative Surgical ProceduresPathologicPatientsPhenotypePostoperative PeriodProductionRecoveryRegenerative MedicineRegenerative responseSafetySheepSignal TransductionSiteSkeletal MuscleStem cellsStromal CellsStudy modelsSurgical FlapsSystemTechnologyTendon structureTestingTimeTissue EngineeringTissue GraftsTissuesTransplantationTraumaTraumatic injuryUndifferentiatedVascularizationWorkbonebone healingcapillarycell typeclinical applicationclinically relevantfunctional restorationimplantationin vivoin vivo regenerationinjuredinnovative technologiesinsightinterestmalemechanical loadmigrationmuscle engineeringmuscle pharmacologymuscle regenerationmuscular structuremusculoskeletal injurynerve supplynew technologyperoneal nerveprecursor cellpublic health relevanceregenerative therapyrepairedresponsesatellite cellscale upskeletal muscle wastingspatial relationshipstemstem cell biologytissue regeneration
项目摘要
DESCRIPTION (provided by applicant): Multiple pathological conditions including muscle trauma, surgical damage, and myopathies can lead to volumetric muscle loss (VML) resulting in unrecoverable muscle function. To date, the treatments for VML including the muscle flap or graft are not always effective and are hindered by limited tissue availability and donor site morbidity. The creation of engineered muscle tissue with functional myotendinous junctions, tendon- bone anchors and innervation will not only restore the function of a complex tissue, e.g. a small facial muscle following traumatic injury or disease, but can also be used as a model for studying developmental muscle biology and muscle pharmacology. To address the need for skeletal muscle replacement tissue, our laboratory has developed a tissue-engineered functional skeletal muscle unit (SMU) of appropriate size and function for clinical use in situations of small VML injuries, such as those found in the hand and face [1-8]. Our SMU is a multi-phasic composite tissue consisting of engineered muscle tissue with engineered tendon and/or bone- tendon anchor ends. After twenty-eight days of exposure in vivo to a VML environment, our constructs exhibited significant alteration to the SMU phenotype including uniaxial aligned muscle fibers encased in an extensive extra-cellular matrix, complete bone healing at the bone attachment, formation of enthesis and myotendinous interfaces , extensive vascularization and innervation with concomitant formation of neuromuscular junctions (8). This exciting technology actually results in the addition of new muscle fibers to the repair area. Our findings show that our multi-phasic composite tissue survives implantation, survives the mechanical loads placed on them in vivo, and develops the necessary interfaces needed to advance the phenotype toward adult muscle structure and function. While our technology shows great promise for the repair of damaged muscle, a lot of work remains to determine how best to utilize this technology to obtain optimal recovery of muscle function to an injury site. For example, we need more complete recovery of native muscle forces. An additional concern regarding the use of this novel and innovative technology in humans is the safety of use of stem/precursor cell-derived tissue in patients. It is imperative that the primary or stromal cells used for the generation of these tissue constructs pose no acute or long-term threat after implantation. The main concern in the field is the ability to ascertain that no undifferentiated cels persist in the transplanted construct that might later lead to aberrant cellular behavior such as cancer. Thus, to progress this technology towards clinical application, the mechanisms of graft tissue integration, regeneration, and repair must be elucidated. The overall goal of this proposal is to use VML as a model for looking mechanistically at the integration and regeneration of our SMU tissue following implantation into an appropriate inductive tissue environment. This work has broad implications for stem cell biology, musculoskeletal biology and regenerative medicine as well as direct clinical relevance for the treatment of musculoskeletal tissue injuries.
描述(由申请人提供):包括肌肉创伤、手术损伤和肌病在内的多种病理状况可能导致体积性肌肉损失(VML),从而导致肌肉功能无法恢复。迄今为止,包括肌瓣或移植在内的 VML 治疗并不总是有效,并且受到有限的组织可用性和供体部位发病率的阻碍。具有功能性肌腱连接、腱骨锚定和神经支配的工程化肌肉组织的创建不仅可以恢复复杂组织的功能,例如肌肉组织。创伤性损伤或疾病后的小面部肌肉,但也可以用作研究发育肌肉生物学和肌肉药理学的模型。为了满足骨骼肌替代组织的需求,我们的实验室开发了一种具有适当大小和功能的组织工程功能性骨骼肌单元 (SMU),可用于临床上小型 VML 损伤的情况,例如手和面部的损伤 [1-8]。我们的 SMU 是一种多相复合组织,由工程肌肉组织和工程肌腱和/或骨肌腱锚定端组成。在体内暴露于 VML 环境 28 天后,我们的构建体表现出 SMU 表型的显着改变,包括包裹在广泛的细胞外基质中的单轴排列的肌纤维、骨附着处的完全骨愈合、附着点和肌腱界面的形成、广泛的血管化和神经支配,同时形成神经肌肉接头 (8)。这项令人兴奋的技术实际上会在修复区域添加新的肌肉纤维。我们的研究结果表明,我们的多相复合组织在植入后仍能存活,在体内承受机械负载后仍能存活,并形成将表型推进成人肌肉结构和功能所需的必要界面。虽然我们的技术在修复受损肌肉方面显示出巨大的前景,但仍有大量工作需要确定如何最好地利用该技术来实现损伤部位肌肉功能的最佳恢复。例如,我们需要更完全地恢复原生肌肉力量。关于在人类中使用这种新颖和创新技术的另一个问题是在患者中使用干细胞/前体细胞衍生组织的安全性。至关重要的是,用于生成这些组织构建体的原代细胞或基质细胞在植入后不会造成急性或长期威胁。该领域主要关注的是能否确定移植结构中是否存在未分化细胞,这些细胞随后可能导致异常细胞行为,例如癌症。因此,为了将该技术推向临床应用,必须阐明移植组织整合、再生和修复的机制。该提案的总体目标是使用 VML 作为模型,从机制上研究我们的 SMU 组织在植入适当的感应组织环境后的整合和再生。这项工作对干细胞生物学、肌肉骨骼生物学和再生医学具有广泛的影响,并对肌肉骨骼组织损伤的治疗具有直接的临床意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LISA M LARKIN其他文献
LISA M LARKIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LISA M LARKIN', 18)}}的其他基金
Planning for clinical trial of fully-biologic, cell generated graft (CGEM) for ACLrepair
规划用于 ACL 修复的全生物细胞生成移植物 (CGEM) 的临床试验
- 批准号:
10724487 - 财政年份:2023
- 资助金额:
$ 47.36万 - 项目类别:
Non-Invasive, Quantitative, and Label-Free Characterization of Tissue Engineered Skeletal Muscle
组织工程骨骼肌的非侵入性、定量和无标记表征
- 批准号:
9894756 - 财政年份:2019
- 资助金额:
$ 47.36万 - 项目类别:
Utilization of Engineered Skeletal Muscle Units to Repair Volumetric Muscle
利用工程骨骼肌单位修复体积肌
- 批准号:
9198665 - 财政年份:2015
- 资助金额:
$ 47.36万 - 项目类别:
Engineering Innervated Muscle-Tendon Constructs for Tissue Regeneration
工程神经支配的肌肉肌腱结构用于组织再生
- 批准号:
7847858 - 财政年份:2009
- 资助金额:
$ 47.36万 - 项目类别:
Engineering Innervated Muscle-Tendon Constructs for Tissue Regeneration
工程神经支配的肌肉肌腱结构用于组织再生
- 批准号:
8046434 - 财政年份:2007
- 资助金额:
$ 47.36万 - 项目类别:
Engineering Innervated Muscle-Tendon Constructs for Tissue Regeneration
工程神经支配的肌肉肌腱结构用于组织再生
- 批准号:
7758217 - 财政年份:2007
- 资助金额:
$ 47.36万 - 项目类别:
Electromechanical Stimuli on the Development of Engineered Myotendinous Junction
机电刺激对工程化肌腱接头发育的影响
- 批准号:
7177233 - 财政年份:2007
- 资助金额:
$ 47.36万 - 项目类别:
Engineering Innervated Muscle-Tendon Constructs for Tissue Regeneration
工程神经支配的肌肉肌腱结构用于组织再生
- 批准号:
7574397 - 财政年份:2007
- 资助金额:
$ 47.36万 - 项目类别:
Engineering Innervated Muscle-Tendon Constructs for Tissue Regeneration
工程神经支配的肌肉肌腱结构用于组织再生
- 批准号:
7241958 - 财政年份:2007
- 资助金额:
$ 47.36万 - 项目类别:
Engineering Innervated Muscle-Tendon Constructs for Tissue Regeneration
工程神经支配的肌肉肌腱结构用于组织再生
- 批准号:
7405408 - 财政年份:2007
- 资助金额:
$ 47.36万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 47.36万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 47.36万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 47.36万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 47.36万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 47.36万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 47.36万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 47.36万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 47.36万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 47.36万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 47.36万 - 项目类别:
Research Grant














{{item.name}}会员




